Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma
- PMID: 19200837
- PMCID: PMC3487399
- DOI: 10.1016/j.vaccine.2009.01.061
Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma
Abstract
Cervical cancer is mainly associated with HPV genotype 16 infection. Recombinant measles virus (rMV) expressing HPV genotype 16 L1 capsid protein was generated by construction of an antigenomic plasmid, followed by rescue using the human "helper" cell line 293-3-46. In cell cultures the recombinant MV-L1 virus replicated practically as efficiently as the standard attenuated MV established as commercial vaccine, devoid of the transgene. The high genetic stability of MVb2-L1 was confirmed by 10 serial viral transfers in cell culture. In transgenic mice expressing the MV receptor CD46 the recombinant induced strong humoral immune responses against both MV and HPV; the antibodies against L1 exhibited mainly neutralizing capacity. Our data suggest that MV is a promising vehicle for development of inexpensive and efficient vaccines protecting from HPV infection.
Figures
Similar articles
-
Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine.Vaccine. 2016 Sep 7;34(39):4724-4731. doi: 10.1016/j.vaccine.2016.07.051. Epub 2016 Aug 11. Vaccine. 2016. PMID: 27523740 Free PMC article.
-
Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.Clin Vaccine Immunol. 2007 Oct;14(10):1285-95. doi: 10.1128/CVI.00164-07. Epub 2007 Aug 8. Clin Vaccine Immunol. 2007. PMID: 17687110 Free PMC article.
-
HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.Hum Vaccin Immunother. 2014;10(12):3491-8. doi: 10.4161/hv.36084. Hum Vaccin Immunother. 2014. PMID: 25483698 Free PMC article.
-
Developments in L2-based human papillomavirus (HPV) vaccines.Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23. Virus Res. 2017. PMID: 27889616 Free PMC article. Review.
-
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.Immunol Cell Biol. 2009 May-Jun;87(4):287-99. doi: 10.1038/icb.2009.13. Immunol Cell Biol. 2009. PMID: 19421199 Free PMC article. Review.
Cited by 23 articles
-
Self-replicating vehicles based on negative strand RNA viruses.Cancer Gene Ther. 2022 Feb 15:1-14. doi: 10.1038/s41417-022-00436-7. Online ahead of print. Cancer Gene Ther. 2022. PMID: 35169298 Free PMC article. Review.
-
Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer.Vaccines (Basel). 2021 Oct 15;9(10):1187. doi: 10.3390/vaccines9101187. Vaccines (Basel). 2021. PMID: 34696295 Free PMC article. Review.
-
Engineering and combining oncolytic measles virus for cancer therapy.Cytokine Growth Factor Rev. 2020 Dec;56:39-48. doi: 10.1016/j.cytogfr.2020.07.005. Epub 2020 Jul 3. Cytokine Growth Factor Rev. 2020. PMID: 32718830 Free PMC article. Review.
-
Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.Front Immunol. 2018 Nov 12;9:2478. doi: 10.3389/fimmu.2018.02478. eCollection 2018. Front Immunol. 2018. PMID: 30483247 Free PMC article. Review.
-
Measles-derived vaccines to prevent emerging viral diseases.Microbes Infect. 2018 Oct-Nov;20(9-10):493-500. doi: 10.1016/j.micinf.2018.01.005. Epub 2018 Feb 1. Microbes Infect. 2018. PMID: 29410084 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
